Yes. Thank you, Robin. I’ll start with the last question. And then the other questions, I will kind of give it to Steve and Tanate here. So return on equity, well, it’s the first time that we stepped out of that range. It is particularly because of the last quarter here. So yes, we’re not happy with that. Indeed, the further pressure on capital will have an effect on that. Having said that, so we’re looking at a lower rate environment. We may have some capital increases coming still. We have some regulatory costs. We have some KYC costs. But on the other side, we’re also management. And as management, we are here to manage this kind of things. So the big thing still stays: our strategy of making sure that we move to a platform, that we get more customers, that they buy more products, that we charge more fees on the back of selling products, that we expand in also in non-euro areas, that we decrease the cost to serve because of digitalization. So that’s how you manage it. Now clearly, from a more how do you go about pricing perspective, as you see this year both in wholesale as well as in retail, we have pricing discipline. And we don’t mind to walk away from business if it doesn’t yield a return that we need to have. As a diversified bank in many different geographies and many different sectors in Wholesale Banking side, we have the opportunity because we’re not tied to one specific geography like some of our competitors have. So the repricing is happening, and we will continue with that discipline. Then it’s to continue to grow the lending book versus the cost. So you should expect that we will continue to improve in what we call operating leverage. Then it is a change in lending mix, which we will continue to do, moving to a higher NIM lending businesses. So that’s kind of still how we think we can manage things. Will we kind of be able to be back in the 10% to 12% tomorrow? We’ll have to see, work hard on it. But at this moment, the guidance that we have is the guidance that we keep. Maybe then on capital, Steven, and then on B2R,Tanate.